{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:43Z","timestamp":1789621483517,"version":"build-2803163510"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2026.1931505","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:45:23Z","timestamp":1789620323000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Jian","family":"Zheng","sequence":"first","affiliation":[{"name":"Zhejiang Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyang","family":"Chi","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial Hospital of Chinese Medicine, The First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2312","article-title":"Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy","volume":"32","author":"Garralda","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1883","article-title":"Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST Working Group","volume":"30","author":"Wyatt","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-100311","article-title":"ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol","volume":"16","author":"Andersen","year":"2026","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","unstructured":"Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development: Guidance for Industry\n          \n          \n          \n          2024"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:45:42Z","timestamp":1789620342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1931505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":11,"alternative-id":["10.3389\/fonc.2026.1931505"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1931505","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1931505"}}